Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro

Oncology Research

Volumn 12, Issue 3, 2000, Pages 137-148

  Kano, Yasuhiko ^a   Akutsu, Miyuki ^a   Suzuki, Kenichi ^a   Yazawa, Yasuo ^a   Tsunoda, Saburo ^a   Furukawa, Yusuke ^b  

^a TOCHIGI CANCER CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Drug combination; Isobologram; Raltitrexed

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; QUINAZOLINE DERIVATIVE; RALTITREXED; THIOPHENE DERIVATIVE;

ARTICLE; CELL CULTURE; COLON TUMOR; DOSE RESPONSE; DRUG ADMINISTRATION; HUMAN; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; QUINAZOLINES; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0034569558     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747611     Document Type: Article

References (37)

1. Grem, J. L. 5-Fluoropyrimidines. In: Chabner, B. A.; Longo, D. L., eds. Cancer chemotherapy and biolherapy. Philadelphia: Lippincott-Raven; 1996:149-212.
2. Jackman, A. L.; Taylor, G. A.; O'Connor, B. M.; Bishop, J. A.; Moran, R. G.; Calvert, A. H. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murinc (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res. 50:5212-5218; 1990.
3. Jackman, A. L.; Taylor, G. A.; Gibson, W.; Kimbell, R.; Brown, M.; Calvert, A. H.; Judson, I. R.; Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res. 51:5579-5586; 1991.
4. Takemura, Y.; Jackman, A. L. Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anticancer Drugs 8:3-16; 1997.
5. Clarke, S. J.; Hanwell, J.; de Boer, M.; Planting, A.; Verweij, J.; Walker, M.; Smith, R.; Jackman, A. L.; Hughes, L. R.; Harrap, K. R.; Kennealey, G. T.; Judson, I. R. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J. Clin. Oncol. 14:1495-1503;1996.
6. 14C]-raltitrexed in cancer patients. Cancer Chemother. Pharmacol. 42:71-76; 1998.
7. Smith, I.; Jones, A.; Spielmann, M.; Namer, M.; Green, M. D.; Bonneterre, J.; Wander, H. E.; Halschek, T.; Wilking, N.; Zalcberg, J.; Spiers, J.; Seymour, L. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br. J. Cancer 74:479-481;1996.
8. Zalcberg, J. R.; Cunningham, D.; Van Cutsem, E.; Francois, E.; Schornagel, J.; Adenis, A.; Green, M.; Iveson, A.; Azab, M.; Seymour, I. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J. Clin. Oncol. 14:716-721; 1996.
9. Cunningham, D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br. J. Cancer 77(Suppl. 2):15-21; 1998.
10. Anderson, H.; Palmer, M. K. Measuring quality of life: Impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. Br. J. Cancer 77(Suppl. 2):9-14; 1998.
11. Cocconi, G.; Cunningham, D.; Van Cutsem, E.; Francois, E.; Gustavsson, B.; van Hazel, G.; Kerr, D.; Possinger, K.; Hietschold, S. M. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J. Clin. Oncol. 16:2943; 1998.
12. Cunningham, D.; Zalcberg, J. R.; Rath, U.; Oliver, I.; Van Cutsem, E.; Svensson, C.; Seitz, J. F.; Harper, P.; Kerr, D.; Perez-Manga, G. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. 'Tomudex' Colorectal Cancer Study Group. Ann. Oncol. 7:961-965; 1996.
13. Harper, P. Advanced coloreclal cancer: Results from the latest Tomudex comparative study. Proc. Am. Soc. Clin. Oncol. 16:802; 1997.
14. Pazdur, R.; Vincent, M. Raltitrexed vs 5-fluorouacil + leucovorin in patients with advanced clorectal cancer: Results of a randomized multicenter North American Trial. Proc. Am. Soc. Clin. Oncol. 16:801; 1997.
15. Harstrick, A.; Mayer, S.; Muller, C.; Hilger, R.; Dohmen, D.; Kreisel, C.; Vanhoefer, U.; Scheulen, M. E.; Wilke, H.; Seeber, S. Combination therapy with infusional 5-FU and Tomudex for patients with advanced colorectal cancer - a phase I study. Proc. Am. Soc. Clin. Oncol. 17:772; 1998.
16. Caponigro, F.; Avallone, A.; McLeod, H.; Carteni, G.; De Vita, F.; Casaretti, R.; Morsman, J.; Blackie, R.; Budillon, A.; De Lucia, L.; Gravina, A.; Catalano, G.; Comelia, P.; Comella, G. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. Clin. Cancer Res. 5:3948-3955; 1999.
17. Schwartz, G. K.; Harstrick, A.; Gonzalez Baron, M. Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: Preliminary results from phase I clinical trials. Eur. J. Cancer 35(Suppl. 1):9-13; 1999.
18. Harstrick, A.; Schleucher, N.; Gonzales, A.; Schmidt, C.; Hoffman, A.; Wilke, H.; Rustum, Y.; Seeber, S. Interactions and cross resistance patterns between various schedules of 5-FU and the new, folate-based thymidylate synthase inhibitor tomudex (ZD1694). Eur. J. Cancer. 31A(Suppl. 5):S30; 1995.
19. Van der Wilt, C. L.; Pinedo, H. M.; Kuiper, C. M.; Smid, K.; Peters, G. J. Biochemical basis for the combined antiproliferative effect of AG337 or ZD1694 and 5-fluorouracil. Proc. Am. Assoc. Cancer Res. 36:2260; 1995.
20. Chang, Y. M.; Zielinski, Z.; Izzo, J.; Porubcin, M.; Bertino, J. R. Pretreatment of colon carcinoma cells to D1694 (Tomudex) markedly enhances 5-fluorouracil cytotoxicity. Proc. Am. Assoc. Cancer Res. 35:1966; 1996.
21. Kimbel, R.; Brunton, L.; Jackman, A. L. Combination studies with Tomudex and 5-fluorouracil in human colon tumour cell lines. Br. J. Cancer 73(Suppl. 16):P12; 1996.
22. Longo, G. S.; Izzo, J.; Chang, Y. M.; Tong, W. P.; Zielinski, Z.; Gorlick, R.; Chou, T. C.; Bcrtino, J. R. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. Clin. Cancer Res. 4:469-473; 1998.
23. Kano, Y.; Sakamoto, S.; Kasahara, T.; Akutsu, M.; Inoue, Y.; Miura, Y. In vitro effects of amsacrine in combination with other anticancer agents. Leukemia Res. 15:1059-1064; 1991.
24. Steel, G. G.; Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int. J. Radial. Oncol. 5:8-91; 1979.
25. Kano, Y.; Ohnuma, T.; Okano, T.; Holland, J. F. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res. 48:351-356; 1988.
26. Kano, Y.; Suzuki, K.; Akutsu, M.; Suda, K.; Inoue, Y.; Yoshida, M.; Sakamoto, S.; Miura, Y. Effects of CPT-11 in combination with other anticancer agents in culture. Int. J. Cancer 50:604-609; 1992.
27. Kano, Y.; Akutsu, M.; Tsunoda, S.; Suzuki, K.; Adachi, K. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother. Pharmacol. 42:91-98; 1998.
28. Izzo, J.; Zielinski, Z.; Chang, Y. M.; Bertino, J. R. Molecular mechanisms of the synergistic sequential administration of ZD1694 (Tomudex) followed by Fura in colon carcinoma cells. Proc. Am. Assoc. Cancer Res. 36:2272; 1995.
29. Inaba, M.; Mitsuhashi, J. Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. Oncol. Res. 6:303-309; 1994.
30. Aschele, C.; Sobrero, A.; Faderan, M. A.; Bertino, J. R. Novel mechanisms of resistance to 5-fluorouracil in human colon cancer (HT-8) sublines. Cancer Res. 52:1855-1864; 1992.
31. Berenbaum, M. C. What is synergy? Pharmacol. Rev. 41:93-141; 1988.
32. Frey, C. M. Role of modelling in joint action studies. J. Natl: Cancer Inst. 86:1493-1495; 1994.
33. Greco, W. R.; Bravo, G.; Parsons, J. C. The search for synergy: A critical review from a response surface perspective. Pharmacol. Rev. 47:331-385; 1995.
34. Rideout, D. C.; Chou, T. C. Synergism, antagonism, and potentiation of chemotherapy. In: Chou, T. C.; Rideout, D. C., eds. Synergism and antagonism in chemothrapy. San Diego: Academic Press; 1991:3-60.
35. Webb, J. L. Effect of more than one inhibitor. In: Enzymes and metabolic inhibitors, vol. 1. New York: Academic Press; 1963: 66-79.
36. Loewe, S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3:285-290; 1953.
37. Chou, T. C.; Motzer, R. J.; Tong, Y.; Bosl, G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human tcratocarcinoma cell growth: A rational approach to clinical protocol design. J. Natl. Cancer Inst. 86: 1517-1524; 1994.